CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] CRO SERVICES AGREEMENTCro Services Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • California
This CRO Services Agreement (“Agreement”) is made effective as of the 15th day of September 2004 by and between BioMarin Pharmaceutical Inc., a Delaware corporation (“BIOMARIN”), and Kendle International Inc., an Ohio corporation (“CRO”).
SETTLEMENT AGREEMENT AND MUTUAL RELEASESettlement Agreement and Mutual Release • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations • New York
THIS SETTLEMENT AGREEMENT AND MUTUAL RELEASE (this “Agreement”) is executed as of January 12, 2005, by and among BioMarin Pharmaceutical Inc., a Delaware corporation, BioMarin Pediatrics Inc., a Delaware corporation and wholly-owned subsidiary of BioMarin Pharmaceutical Inc., Medicis Pharmaceutical Corporation, a Delaware corporation, and Medicis Pediatrics, Inc., a Delaware corporation (formerly known as Ascent Pediatrics, Inc.) and a wholly-owned subsidiary of Medicis Pharmaceutical Corporation. BioMarin Pharmaceutical Inc. and BioMarin Pediatrics Inc. are collectively referred to as “BioMarin” and Medicis Pharmaceutical Corporation and Medicis Pediatrics, Inc. are collectively referred to as “Medicis.” BioMarin and Medicis are jointly referred to as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] LICENSE AGREEMENTLicense Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
This License Agreement (hereinafter referred to as the “Agreement”) made and entered into as of July 30, 2004 (hereinafter referred to as the “Effective Date”) by and between DAIICHI SUNTORY PHARMA CO., LTD., a corporation organized and existing under the laws of Japan and having its registered office at 7-2, Kojimachi 5-chome, Chiyoda-ku, Tokyo 102-8530, Japan (hereinafter referred to as “DSP”) and BIOMARIN PHARMACEUTICAL INC., a corporation organized and existing under the laws of the State of Delaware, having its principal business office at 371 Bel Marin Keys Blvd., Suite 210, Novato, California 94949, U.S.A. (hereinafter referred to as “BIOMARIN”). DSP and BIOMARIN are sometimes referred to as the “Parties” collectively or as a “Party” individually.
AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
THIS AMENDMENT TO SECURITIES PURCHASE AGREEMENT (this “Amendment”) is executed as of January 12, 2005, by and among BioMarin Pharmaceutical Inc., a Delaware corporation, BioMarin Pediatrics Inc., a Delaware corporation and wholly-owned subsidiary of BioMarin Pharmaceutical Inc., Medicis Pharmaceutical Corporation, a Delaware corporation, and Medicis Pediatrics, Inc. (formerly known as Ascent Pediatrics, Inc.), a Delaware corporation, a wholly-owned subsidiary of Medicis Pharmaceutical Corporation. Each is referred to herein as a “Party” and collectively as the “Parties.”
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
This Second Amendment to Loan and Security Agreement is entered into as of February 15, 2005 (the “Amendment”), by and between COMERICA BANK (“Bank”) and BIOMARIN PHARMACEUTICAL INC. (“Borrower”).
AMENDMENT TO LICENSE AGREEMENTLicense Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
THIS AMENDMENT TO LICENSE AGREEMENT (this “Amendment”) is executed as of January 12, 2005, by and among BioMarin Pharmaceutical Inc., a Delaware corporation, BioMarin Pediatrics Inc., a Delaware corporation and wholly-owned subsidiary of BioMarin Pharmaceutical Inc., Medicis Pharmaceutical Corporation, a Delaware corporation, and Medicis Pediatrics, Inc. (formerly known as Ascent Pediatrics, Inc.), a Delaware corporation, a wholly-owned subsidiary of Medicis Pharmaceutical Corporation. Each is referred to herein as a “Party” and collectively as the “Parties.”
CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] SUPPLY AGREEMENTSupply Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
This Supply Agreement (hereinafter referred to as the “Supply Agreement”) is dated July 30, 2004 (hereinafter called the “Effective Date”) by and between DAIICHI SUNTORY PHARMA CO., LTD., a corporation organized and existing under the laws of Japan and having its registered office at 7-2, Kojimachi 5-chome, Chiyoda-ku, Tokyo 102-8530, Japan (hereinafter referred to as “DSP”) and BIOMARIN PHARMACEUTICAL INC., a corporation organized and existing under the laws of the State of Delaware, having its principal business office at 371 Bel Marin Keys Blvd., Suite 210, Novato, California 94949, U.S.A. (hereinafter referred to as “BIOMARIN”), and SHIRATORI PHARMACEUTICAL CO., LTD. a corporation organized and existing under the laws of Japan and having its principal business office at 2-3-7 Akanehama, Narashino City, Chiba 275-0024, Japan (hereinafter referred to as “SHIRATORI”). DSP, BIOMARIN and SHIRATORI are each a “Party” and collectively, the “Parties.”
SEVERANCE AGREEMENT AND RELEASE OF ALL CLAIMSSeverance Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
CONFIDENTIAL TREATMENT REQUESTED Redacted Portions are indicated by [****] License AgreementLicense Agreement • March 16th, 2005 • Biomarin Pharmaceutical Inc • Pharmaceutical preparations
